United States Pharmaceuticals

Arvinas Inc (ARVN)

Track

Over the past 90 days, Arvinas Inc. insiders have engaged in 16 transactions, all of which were sales, resulting in a net negative value of approximately $518,078. Key executives, including the CEO, CFO, and CSO, have consistently sold shares. These transactions follow the company's May 2026 earnings report and coincide with a 21.1% decline in stock price.
Ticker: ARVN Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Arvinas Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Proposed sale 9 Jul 2026
Value US$2,620,527.24 | Price 127.85 | Shares 62,082
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-09 2026-07-09 PrS Proposed sale
3.7
NOAH C BERKOWITZ

Former Affiliate
62,082
127.85
US$2,620,527 		62,082 127.85 US$2,620,527
2026-06-24 2026-06-24 S Sale
3.6
Saik Andrew

Chief Financial Officer

Officer
74,915 +29.7%
312.69
US$1,877,038 		74,915 +29.7% 312.69 US$1,877,038
2026-06-23 2026-06-24 PrS Proposed sale
3.6
Andrew Saik

Officer

Officer
93,345
343.00
US$688,633 		93,345 343.00 US$688,633
2026-06-18 2026-06-17 S Sale
3.8
Cacace Angela M

Chief Scientific Officer

Officer
2,576 -1.4%
7.60
US$19,565 		2,576 -1.4% 7.60 US$19,565
2026-06-17 2026-06-17 PrS Proposed sale
3.8
Angela Cacace

Officer

Officer
2,642
7.42
US$19,604 		2,642 7.42 US$19,604
2026-05-22 2026-05-21 S Sale
3.6
Teel Randy

President and CEO

Executive Director
2,209 -0.8%
9.04
US$19,962 		2,209 -0.8% 9.04 US$19,962
2026-05-20 2026-05-21 PrS Proposed sale
3.6
Randy Teel

Officer; Director

Executive Director
2,197
9.10
US$19,993 		2,197 9.10 US$19,993
2026-05-13 2026-05-11 S Sale
3.9
Loomis David K

VP, Chief Accounting Officer

Officer
1,919 -4.6%
9.94
US$19,070 		1,919 -4.6% 9.94 US$19,070
2026-05-13 2026-05-11 S Sale
3.6
Saik Andrew

Chief Financial Officer

Officer
11,139 -5.5%
9.94
US$110,693 		11,139 -5.5% 9.94 US$110,693
2026-05-13 2026-05-11 S Sale
3.8
Cacace Angela M

Chief Scientific Officer

Officer
9,657 -5.0%
9.94
US$95,965 		9,657 -5.0% 9.94 US$95,965
2026-05-13 2026-05-11 S Sale
3.7
Berkowitz Noah

Chief Medical Officer

Officer
11,108 -5.5%
9.94
US$110,385 		11,108 -5.5% 9.94 US$110,385
2026-05-13 2026-05-11 S Sale
3.6
Teel Randy

President and CEO

Executive Director
9,657 -3.3%
9.94
US$95,965 		9,657 -3.3% 9.94 US$95,965
2026-05-08 2026-05-11 PrS Proposed sale
3.6
Andrew Saik

Officer

Officer
11,343
10.11
US$114,678 		11,343 10.11 US$114,678
2026-05-08 2026-05-11 PrS Proposed sale
3.8
Angela Cacace

Officer

Officer
9,834
10.11
US$99,422 		9,834 10.11 US$99,422
2026-05-08 2026-05-11 PrS Proposed sale
3.7
Noah Berkowitz

Officer

Officer
11,312
10.11
US$114,364 		11,312 10.11 US$114,364
2026-05-08 2026-05-11 PrS Proposed sale
3.6
Randy Teel

Officer; Director

Executive Director
9,834
10.11
US$99,422 		9,834 10.11 US$99,422
2026-03-19 2026-03-18 S Sale
3.7
Berkowitz Noah

Chief Medical Officer

Officer
6,435 -3.1%
11.10
US$71,431 		6,435 -3.1% 11.10 US$71,431
2026-03-17 2026-03-18 PrS Proposed sale
3.7
Noah Berkowitz

Officer

Officer
6,022
12.01
US$72,324 		6,022 12.01 US$72,324
2026-03-09 2026-03-06 B Purchase
3.3
Morrison Briggs
Non-Executive Director
20,000 +26.3%
13.40
US$268,070 		20,000 +26.3% 13.40 US$268,070
2026-03-02 2026-02-27 S Sale
4.2
Houston John G
Non-Executive Director
11,787 -1.0%
13.14
US$154,881 		11,787 -1.0% 13.14 US$154,881
2026-03-02 2026-02-27 S Sale
4.2
Houston John G
Non-Executive Director
18,822 -1.6%
13.24
US$249,203 		18,822 -1.6% 13.24 US$249,203
2026-03-02 2026-02-27 S Sale
4.2
Houston John G
Non-Executive Director
4,688 -0.4%
13.24
US$62,069 		4,688 -0.4% 13.24 US$62,069
2026-02-27 2026-02-27 PrS Proposed sale
4.2
John G. Houston

former President and CEO; Director

Non-Executive Director
35,297
13.21
US$466,184 		35,297 13.21 US$466,184
2026-02-25 2026-02-23 S Sale
3.9
Loomis David K

Chief Accounting Officer

Officer
1,108 -3.6%
12.16
US$13,473 		1,108 -3.6% 12.16 US$13,473
2026-02-25 2026-02-23 S Sale
3.8
Cacace Angela M

Chief Scientific Officer

Officer
2,571 -1.7%
12.16
US$31,263 		2,571 -1.7% 12.16 US$31,263
2026-02-25 2026-02-23 S Sale
3.8
Cacace Angela M

Chief Scientific Officer

Officer
1,038 -0.7%
12.16
US$12,622 		1,038 -0.7% 12.16 US$12,622
2026-02-25 2026-02-23 S Sale
3.6
Teel Randy

President and CEO

Executive Director
3,748 -2.4%
12.16
US$45,576 		3,748 -2.4% 12.16 US$45,576
2026-02-25 2026-02-23 S Sale
3.6
Teel Randy

President and CEO

Executive Director
1,038 -0.7%
12.16
US$12,622 		1,038 -0.7% 12.16 US$12,622
2026-02-23 2026-02-23 PrS Proposed sale
3.8
Angela Cacace

Officer

Officer
3,609
12.16
US$43,897 		3,609 12.16 US$43,897
2026-02-23 2026-02-23 PrS Proposed sale
3.6
Randy Teel

Officer; Director

Executive Director
4,786
12.16
US$58,213 		4,786 12.16 US$58,213
2026-02-18 2026-02-13 S Sale
3.6
Teel Randy

President and CEO

Executive Director
4,403 -2.8%
11.89
US$52,352 		4,403 -2.8% 11.89 US$52,352
2026-02-18 2026-02-13 S Sale
3.6
Saik Andrew

Chief Financial Officer

Officer
5,134 -3.1%
11.89
US$61,043 		5,134 -3.1% 11.89 US$61,043
2026-02-18 2026-02-13 PlS Planned sale
3.8
Cacace Angela M

Chief Scientific Officer

Officer
4,592 -2.9%
11.89
US$54,599 		4,592 -2.9% 11.89 US$54,599
2026-02-18 2026-02-13 S Sale
3.7
Berkowitz Noah

Chief Medical Officer

Officer
5,685 -3.4%
11.89
US$67,595 		5,685 -3.4% 11.89 US$67,595
2026-02-18 2026-02-13 PlS Planned sale
3.9
Loomis David K

Chief Accounting Officer

Officer
1,016 -3.2%
11.89
US$12,080 		1,016 -3.2% 11.89 US$12,080
2026-02-13 2026-02-13 PrS Proposed sale
3.8
Angela Cacace

Officer

Officer
4,592
11.89
US$54,608 		4,592 11.89 US$54,608
2026-02-13 2026-02-13 PrS Proposed sale
3.6
Andrew Saik

Officer

Officer
5,134
11.89
US$61,053 		5,134 11.89 US$61,053
2026-02-13 2026-02-13 PrS Proposed sale
3.7
Noah Berkowitz

Officer

Officer
5,685
11.89
US$67,605 		5,685 11.89 US$67,605
2026-02-13 2026-02-13 PrS Proposed sale
3.6
Randy Teel

Officer

Officer
4,403
11.89
US$52,360 		4,403 11.89 US$52,360
2025-11-07 2025-11-07 PlS Planned sale
3.9
Loomis David K

Chief Accounting Officer

Officer
230 -0.7%
9.89
US$2,275 		230 -0.7% 9.89 US$2,275
2025-09-24 2025-09-22 B Purchase
3.3
Morrison Briggs
Non-Executive Director
30,000 +65.2%
7.57
US$227,010 		30,000 +65.2% 7.57 US$227,010
2025-06-24 2025-06-24 S Sale
3.6
Saik Andrew

Chief Financial Officer

Officer
5,700 -3.4%
7.61
US$43,377 		5,700 -3.4% 7.61 US$43,377
2025-06-23 2025-06-24 PrS Proposed sale
3.6
Andrew Saik

Officer

Officer
5,927
7.35
US$43,593 		5,927 7.35 US$43,593
2025-06-18 2025-06-17 S Sale
3.8
Cacace Angela M

Chief Scientific Officer

Officer
2,583 -1.6%
7.49
US$19,347 		2,583 -1.6% 7.49 US$19,347
2025-03-19 2025-03-18 S Sale
3.7
Berkowitz Noah

Chief Medical Officer

Officer
8,658 -7.3%
8.59
US$74,372 		8,658 -7.3% 8.59 US$74,372
2025-03-18 2025-03-18 PrS Proposed sale
3.7
Noah Berkowitz

Officer

Officer
8,658
8.59
US$74,372 		8,658 8.59 US$74,372
2025-02-25 2025-02-24 S Sale
3.8
Cacace Angela M

Chief Scientific Officer

Officer
1,146 -1.2%
16.55
US$18,966 		1,146 -1.2% 16.55 US$18,966
2025-02-25 2025-02-24 S Sale
3.8
Cacace Angela M

Chief Scientific Officer

Officer
3,061 -3.0%
16.75
US$51,272 		3,061 -3.0% 16.75 US$51,272
2025-02-25 2025-02-24 S Sale
4.2
Houston John G

President and CEO

Executive Director
5,154 -0.4%
16.55
US$85,299 		5,154 -0.4% 16.55 US$85,299
2025-02-25 2025-02-24 S Sale
4.2
Houston John G

President and CEO

Executive Director
26,184 -2.2%
16.75
US$438,582 		26,184 -2.2% 16.75 US$438,582
2025-02-25 2025-02-24 S Sale
3.9
Loomis David K

Chief Accounting Officer

Officer
1,214 -6.0%
16.75
US$20,334 		1,214 -6.0% 16.75 US$20,334
2025-02-25 2025-02-24 S Sale
4.1
Taylor Ian

President, R&D

Officer
1,664 -1.0%
16.55
US$27,539 		1,664 -1.0% 16.55 US$27,539
2025-02-25 2025-02-24 S Sale
4.1
Taylor Ian

President, R&D

Officer
7,356 -4.4%
16.75
US$123,213 		7,356 -4.4% 16.75 US$123,213
2025-02-24 2025-02-24 PrS Proposed sale
4.1
Ian Taylor

Officer

Officer
9,020
16.71
US$150,730 		9,020 16.71 US$150,730
2025-02-24 2025-02-24 PrS Proposed sale
4.2
John G Houston

Officer; Director

Executive Director
31,338
16.71
US$523,801 		31,338 16.71 US$523,801
2025-02-24 2025-02-24 PrS Proposed sale
3.8
Angela M Cacace

Officer

Officer
4,207
16.69
US$70,230 		4,207 16.69 US$70,230
2024-11-12 2024-11-07 S Sale
3.9
Loomis David K

Chief Accounting Officer

Officer
231 -2.8%
27.69
US$6,396 		231 -2.8% 27.69 US$6,396
2024-05-20 2024-05-20 PrS Proposed sale
3.8
Sean Cassidy

retired CFO
50,000
33.00
US$1,650,000 		50,000 33.00 US$1,650,000
2024-05-16 2024-05-16 PrS Proposed sale
3.8
Sean Cassidy

retired CFO
35,000
33.00
US$1,155,000 		35,000 33.00 US$1,155,000
2024-05-15 2024-05-15 PrS Proposed sale
3.8
Sean Cassidy

retired CFO
25,000
33.40
US$835,100 		25,000 33.40 US$835,100
2024-05-13 2024-05-13 PrS Proposed sale
3.8
Sean Cassidy

Officer

Officer
15,000
32.00
US$480,000 		15,000 32.00 US$480,000
2024-02-27 2024-02-23 S Sale
3.2
Peck Ronald

Chief Medical Officer

Officer
1,699 -2.5%
47.05
US$79,938 		1,699 -2.5% 47.05 US$79,938
2024-02-27 2024-02-23 S Sale
4.2
Houston John G

President and CEO

Executive Director
5,196 -0.5%
47.05
US$244,472 		5,196 -0.5% 47.05 US$244,472
2024-02-27 2024-02-23 S Sale
3.8
Cassidy Sean A

Chief Financial Officer

Officer
1,702 -0.9%
47.05
US$80,079 		1,702 -0.9% 47.05 US$80,079
2024-02-27 2024-02-23 S Sale
4.1
Taylor Ian

Chief Scientific Officer

Officer
1,701 -1.1%
47.05
US$80,032 		1,701 -1.1% 47.05 US$80,032
2024-11-12 2023-11-08 S Sale
3.9
Loomis David K

Chief Accounting Officer

Officer
229 -2.7%
17.05
US$3,904 		229 -2.7% 17.05 US$3,904
2023-08-14 2023-08-11 S Sale
3.2
Peck Ronald

Chief Medical Officer

Officer
1,324 -4.2%
24.39
US$32,289 		1,324 -4.2% 24.39 US$32,289
2023-03-03 2023-03-01 S Sale
4.2
Houston John G

President and CEO

Executive Director
5,878 -0.6%
29.53
US$173,577 		5,878 -0.6% 29.53 US$173,577
2023-03-03 2023-03-01 S Sale
3.8
Cassidy Sean A

Chief Financial Officer

Officer
1,745 -0.9%
29.53
US$51,530 		1,745 -0.9% 29.53 US$51,530
2023-03-03 2023-03-01 S Sale
4.1
Taylor Ian

Chief Scientific Officer

Officer
1,051 -1.0%
29.53
US$31,036 		1,051 -1.0% 29.53 US$31,036
2022-08-16 2022-08-12 S Sale
3.2
Peck Ronald

Chief Medical Officer

Officer
1,258 -13.4%
68.99
US$86,794 		1,258 -13.4% 68.99 US$86,794
2022-04-18 2022-04-14 PlS Planned sale
3.3
Morrison Briggs
Non-Executive Director
10,754 -35.0%
67.03
US$720,888 		10,754 -35.0% 67.03 US$720,888
2022-04-18 2022-04-14 PlS Planned sale
3.3
Morrison Briggs
Non-Executive Director
7,104 -18.8%
66.07
US$469,356 		7,104 -18.8% 66.07 US$469,356
2022-04-18 2022-04-14 PlS Planned sale
3.3
Morrison Briggs
Non-Executive Director
3,102 -7.6%
65.24
US$202,372 		3,102 -7.6% 65.24 US$202,372
2022-03-15 2022-03-11 PlS Planned sale
3.8
Cassidy Sean A

Chief Financial Officer

Officer
15,000 -8.5%
70.00
US$1,050,000 		15,000 -8.5% 70.00 US$1,050,000
Explore more

More insider trading research around Arvinas Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America